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Abstract
Background. Valproic acid (VPA) apparent clearance (CL) estimated from total serum concentrations is analogous in elderly
and non-elderly adult patients. As drug–protein binding decreases in old age, the aim of our study was to evaluate the
confounding effect of the serum albumin concentration on the VPA apparent CL in elderly patients.
Methods. In 102 epileptic out-patients treated with VPA in monotherapy, serum total steady-state trough concentrations (Css)
were determined. Css concentrations were normalized for a 42 g/L albumin concentration (CssN), and the apparent CL and
normalized apparent CLN were calculated.
Results. A poor concordance of 53% was found in the classiﬁcation of Css and CssN levels of VPA as subtherapeutic,
therapeutic, or supratherapeutic dose. In the elderly (‡65 years) and non-elderly adult patients, the VPA apparent CL was
similar; however, normalized apparent CLN was signiﬁcantly lower in older patients (P < 0.01), with a 40% median decrease.
Conclusions. Total VPA concentrations should be interpreted with caution, mainly in older patients, in which determination
of unbound or normalized total drug concentrations may be clinically useful. Normalization of total concentrations permits
an estimation of the masking effect of serum albumin concentrations on the VPA apparent CL in elderly patients.
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Introduction
Although valproic acid (VPA) was initially approved
for the treatment of refractory absence seizures, it is
now recognized that it has a broad-spectrum anti-
epileptic activity (1). Similarly, VPA may be effec-
tive in a variety of psychiatric and neurological
diseases such as bipolar disorders, schizophrenia,
depression, neurological pain, migraine headaches,
Alzheimer’s disease, and other neurodegenerative
illnesses (2).
VPA is well absorbed from all oral dosage forms,
with a bioavailability greater than 90%. The drug,
structurally related to free fatty acids, is highly ionized
at physiological pH and therefore presents to a high
degree bound to plasma proteins, primarily to albu-
min (3–5). In conditions of hypoalbuminemia (even
moderate) there is a signiﬁcant increase in the free
fraction (percent unbound) of the drug; likewise, for
total serum concentrations up to 75 mg/mL, VPA is
about 90% bound to albumin, but above this con-
centration binding saturates with an increase of the
free fraction (4).
The effect of age on the VPA pharmacokinetics has
been widely studied, although there is clearly a need
for improved methodology in the assessment of age-
related changes in pharmacokinetics (6). The appar-
ent clearance (CL) calculated from total serum VPA
concentrations is similar in elderly and non-elderly
adult patients (7–10); however, in a clinical context
these ﬁndings must be interpreted with caution, con-
sidering that VPA plasma protein binding decreases in
old age, with an accompanying increase of the free
fraction of the drug (5,8,11).
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diminished plasma protein binding is associated
with a decrease of the serum total concentration (pro-
tein-bound plus free drug), and consequently with an
increased apparent CL; however, it would be mislead-
ing to assume that the amount of drug eliminated per
unit of time is also increased (12). The lower total
concentration of the drug is associated with a lower
protein-bound concentration and increased free frac-
tion, although the unbound concentration and the
amount of drug eliminated per unit of time remain
unchanged. Therefore, the pharmacological effect in
these conditions will be analogous to that produced by
the higher total drug concentration obtained under
normal protein binding conditions for the same daily
dose (12).
The decrease of serum albumin concentrations in
oldageiswellestablished(13),andthemainaimofour
study was to evaluate the confounding effect of albu-
min levels on the calculated apparent CL of VPA from
the serum total concentrations (Css) in elderly epilep-
tic patients. Consequently, the normalized total VPA
concentrations (CssN) for a 42 g/L serum albumin
concentration, which corresponds to the percentile
50 of the reference range for individuals between
25 and 55 years of age (13), were estimated as previ-
ously described (14), and the corresponding normali-
zed apparent clearances (CLN) were calculated.
Patients and methods
102 epileptic outpatients (53 males and 49 females)
w i t ham e a na g e( ± SEM) of 40.2 ± 2.3 years (range
6–94 years) and orally treated with VPA in mono-
therapy were studied. None of them took drugs
known to inﬂuence VPA–p r o t e i nb i n d i n g .I na l l
cases the daily VPA administration was carried out
in multiple doses with the same dosing interval.
B l o o ds a m p l e sw e r et a k e nb e f o r eb r e a k f a s ta n dt h e
morning dose, which had not been modiﬁed for at
least 3 months prior to the study, and therefore the
serum levels of VPA correspond to the trough
steady-state concentrations (Css). This study was
carried out according to the good practice rules
for investigation in humans of the Conselleria de
Sanidade (Regional Ministry of Health) of the Xunta
de Galicia, Spain.
Serum VPA total concentrations were determined
in a Dimension
 
Xpand analyzer using reagents from
Siemens Health Care Inc. (Newark, DE, USA). In
cases with albumin concentrations lower or greater
than 42 g/L (609 mmol/L), total VPA Css levels
were normalized using the expression (14): CssN =
aCss/6.5, where 6.5 corresponds to the VPA
unbound fraction for albuminemia of 42 g/L, and a
is the estimated unbound fraction for a particular
albumin concentration using the hyperbolic equation
of Parent et al. (15): a (%) = Ae
-BX, where X corre-
sponds to albumin concentration (mmol/L), and the
constants A = 130.69 and B = 4.96  10
-3. For
experimental total Css concentrations of VPA greater
than 75 mg/mL, the normalized CssN values were
corrected as previously described (14). The VPA
apparent CL or CLN values were, respectively,
calculated from the serum VPA Css or CssN concen-
trations using a conventional pharmacokinetic proce-
dure (12): CL (or CLN) = [(dose/dosing interval)/Css
(or CssN)]. As in previous studies (9,10), trough
rather than average VPA concentrations were used,
and consequently the reported CL and CLN represent
overestimates of actual values.
Serumactivitiesofalanineaminotransferase(ALT),
aspartate aminotransferase (AST), and gamma-
glutamyl transferase (GGT) and concentrations of
albumin, bilirubin, and creatinine were determined
in an Advia 2400 Chemistry System (Siemens Health
Care Diagnostics Inc.). The platelet count was mea-
suredinbloodsamplescollected2–3hoursbeforehand
in K3EDTA anticoagulated tubes using an Advia
2120 Hematology System (Siemens Health Care
Diagnostics Inc.). The liver ﬁbrosis AST to platelet
ratio index (APRI) was calculated in accordance with
Wai et al. (16): APRI = [AST:URL/platelet count
(10
9/L)]  100, where URL corresponds to the AST
upperreferencelimitsformenandwomen.Glomerular
ﬁltration rate (GFR) was estimated from serum cre-
atinine using the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation (17).
Statistical analysis of data was performed using the
StatGraphics package, and the Kolmogorov–Smirnov
test was applied to check for normality. The Pearson
correlation coefﬁcient and Student’s t-test were used
when the data had aGaussian distribution. Otherwise,
the Spearman correlation coefﬁcient and Mann–
Whitney U test were used. In accordance with the
consensus criteria for determination of drugs and
their metabolites in biological samples (18), the
accepted level for accuracy is a deviation of no
more than 15% from the nominal value. Results
were expressed as mean ± SEM (median).
Results
There was a negative correlation between the serum
albumin concentration and age (r = –0.462,
P < 0.001), with patients older than 65 years of
age presenting a signiﬁcant decrease of the albumin
concentration (P < 0.001) (Table I). In a majority of
patients (n = 97), estimated GFR values were higher
than 60 mL/min/1.73 m
2. In all cases the
42 N. Lampon & J. C. Tutorlevels of bilirubin were lower than the upper limit of
reference (data not shown).
There was a relationship between total Css and
normalized total CssN VPA serum levels (Figure 1).
For total trough VPA serum concentrations a thera-
peutic range of 50–100 mg/mL has been widely
accepted (19), and a considerable proportion of cases
presenting therapeutic Css levels, after its norma-
lization by albumin concentration, present suprather-
apeutic CssN levels, with a modest concordance of
53% in the classiﬁcation of Css and CssN levels as
subtherapeutic, therapeutic, or supratherapeutic.
Table I. Pharmacokinetic and biochemical variables according to age in epileptic patients treated in monotherapy with valproic acid.
£19 years 20–64 years ‡65 years
n (males/females) 24 (14/10) 57 (29/38) 21 (10/11)
Age (years) 13.7 ± 0.9 (15.0) 37.9 ± 1.6 (38.0) 76.9 ± 1.7 (76.0)
VPA dose (mg/day) 836.7 ± 91.0 (800.0)*** 1208.8 ± 52.5 (1200.0) 1066.7 ± 70.3 (1000.0)
VPA Css (mg/mL) 66.4 ± 4.6 (67.5) 67.9 ± 2.3 (68.9) 60.4 ± 4.3 (54.4)
VPA CL (mL/min) 9.2 ± 0.8 (8.8)*** 12.7 ± 0.6 (11.7) 13.9 ± 2.0 (11.45)
VPA a (%) 5.87 ± 0.13 (5.6)* 6.59 ± 0.21 (6.2) 9.92 ± 1.09 (8.5)****
VPA CssN (mg/mL) 76.2 ± 9.7 (59.0) 96.7 ± 10.4 (67.9) 145.3 ± 27.7 (71.1)
VPA CLN (mL/min) 9.3 ± 0.9 (10.0) 11.4 ± 0.8 (11.1) 8.1 ± 0.9 (6.7)**
Albumin (g/L) 44.2 ± 1.0 (45.0)* 43.1 ± 1.0 (43.0) 37.0 ± 1.1 (38.0)****
AST (U/L) 14.7 ± 0.7 (14.5) 15.0 ± 1.1 (14.0) 17.6 ± 3.4 (13.0)
ALT (U/L) 14.9 ± 2.3 (12.0)* 19.9 ± 2.0 (15.0) 17.3 ± 3.7 (13.0)
GGT (U/L) 12.7 ± 3.1 (8.5) 17.0 ± 1.9 (12.0) 25.7 ± 6.8 (13.0)
APRI score 0.28 ± 0.02 (0.24) 0.33 ± 0.03 (0.28) 0.48 ± 0.12 (0.31)
AST/ALT ratio 1.2 ± 0.1 (1.2)**** 0.9 ± 0.1 (0.7) 1.1 ± 0.1 (1.0)***
GFR (mL/min/1.73 m
2) 144.0 ± 3.1 (144.2)**** 102.4 ± 2.6 (102.8) 73.2 ± 4.0 (79.2)****
Statistical signiﬁcance against non-elderly adult patients (20–64 years): *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
Results are expressed as mean ± SEM (median).
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Figure 1. Relationship betweentotal (Css)and albumin normalized total(CssN) concentrations of valproicacidin epileptic patientsof <65 (*)
and ‡65 (.) years of age. The dashed lines correspond to the limits of the valproic acid therapeutic range (50–100 mg/mL).
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were similar in patients aged between 20–40 and
41–64years,andthereforethesepatientswereincluded
in one group of non-elderly adults with age between
20 and 64 years. Results obtained for the VPA daily
doses, Css, CssN, CL, and CLN in the studied patients
grouped according to age are shown in Table I. The
estimated VPA unbound fraction was signiﬁcantly
greater in the group of elderly patients. Signiﬁcant
differences for total VPA Css and CssN concentrations
between the different groups of patients were not
obtained, and the difference between the medians of
CssandCssNwasgreaterthan15%ofmedianCssonly
in elderly patients. With respect to the VPA daily dose
and apparent CL, these variables were signiﬁcantly
lower in patients aged £19 years (P < 0.005).
After normalization of serum VPA levels with the
albumin concentration, the apparent CLN was signif-
icantly decreased by around 40% in elderly patients
(‡65 years). No signiﬁcant correlation was found
between the VPA normalized apparent CLN and
GFR (r = 0.074). The interindividual variation of
the VPA apparent CL was signiﬁcantly higher in
patients aged ‡65 years than in the group of non-
elderly adults (CV = 64% versus CV = 35%); however,
the interindividual variation of the VPA normalized
apparent CLN was similar in both groups of patients
(CV = 50% versus CV = 52%). A dichotomy of the
data based on the patients’ sex did not reveal results
with additional interest.
Calculation of APRI suggests a low likelihood of
signiﬁcant hepatic ﬁbrosis in our VPA-treated patients,
because in 84 cases (83%) the APRI score was £0.4,
excluding the presence of liver ﬁbrosis with a high
level of conﬁdence (16,20), and the APRI score was
only higher than 1.5 in two cases, in which signiﬁcant
liver ﬁbrosis may be supposed (16). In the group of
patients with APRI score >0.4 the VPA apparent CLN
was signiﬁcantly lower (P < 0.05) than in the group
with APRI score £0.4 [7.3 ± 1.1 mL/min (6.5 mL/min)
versus 10.5 ± 0.5 mL/min (10.8 mL/min)]. Likewise,
signiﬁcant negative correlations were found between
the VPA apparent CLN and the APRI (r = –0.258,
P < 0.005), and AST/ALT ratios (r = –0.387,
P < 0.001). The apparent CLN was also signiﬁcantly
correlated with serum ALT (r = 0.280, P < 0.01) and
GGT (r = 0.211, P < 0.05) activities, but not with AST
activity (r = 0.076).
Discussion
Age-related pharmacokinetic changes are due to mul-
tiple factors and present a high interindividual vari-
ability. Gastrointestinal absorption is not generally
altered in elderly; nevertheless, decreased plasma
protein binding, increased volume of distribution,
reduced efﬁciency of drug-metabolizing enzymes,
and diminished drug renal clearance may lead to a
decreased elimination half-life of several drugs in
older patients (11,22).
In accordance with previously published reports
(7–10), the apparent CL of VPA calculated from
the total Css concentrations was analogous in elderly
and non-elderly adult patients (Table I); however, the
serum concentration of albumin was signiﬁcantly
lower in the group with age ‡65 years than in the
other groups that were considered (Table I), and
therefore an increase of the VPA unbound fraction
should be assumed in these elderly patients, as pre-
viously described (5,11,21,22). Normalization of total
VPA Css concentrations permit estimation of the total
CssN levels (the unbound concentrations remain
unchanged) that would be expected if the serum
albumin concentration in all patients was 42 g/L
(14) and consequently a correction of the confound-
ing effect of serum albumin concentrations on the
calculated apparent CL from total VPA levels.
At present, the clinical usefulness of measurements
of VPA unbound concentrations is a debated subject
(19,23); however, decreases in VPA protein binding
are followed by reductions in total serum concentra-
tions, whereas unbound concentrations are
unchanged, and these reduced total concentrations
may be misinterpreted as reﬂecting an inadequate
dosage (24). As previously described for total and
unbound VPA serum concentrations (25,26), a non-
linear, hyperbolic relationship was found between
total Css and total normalized CssN concentrations
(Figure 1). Similarly, a poor concordance of 53% was
obtained in the classiﬁcation of total Css and total
normalized CssN serum VPA levels as subtherapeutic,
therapeutic, or supratherapeutic. The diagnostic efﬁ-
ciency of a laboratory test is the percentage of all
results that are true, and as a general rule a test is
probably not worth doing if its efﬁciency is less than
80% (27). Consequently the results indicated above
suggest an unacceptable diagnostic efﬁciency of the
total Css concentrations for therapeutic VPA moni-
toring in our group of epileptic out-patients. In a
signiﬁcant number of cases (around 47%) the deter-
mination of unbound VPA concentrations, or at least
estimation of total normalized CssN levels, would be
clinically useful. In several cases, with VPA Css con-
centrations in the therapeutic range, the estimated
normalized CssN levels were signiﬁcantly suprather-
apeutic (>200 mg/mL), explaining the hyper-
sedation and dysarthria observed in these patients.
After correction of the masking effect of the albu-
min concentration, the apparent VPA CLN calculated
from the total normalized CssN levels was signiﬁcantly
44 N. Lampon & J. C. Tutorlower in the group of elderly patients than in the non-
elderly adult patients group (P < 0.01). The VPA CLN
median decrease of about 40% in old age (Table I) is
analogous to the difference previously calculated on
apparent CL of unbound VPA (6,28). Also, after
normalization of the total VPA Css concentrations,
the interindividual variation of the normalized appar-
ent CLN calculated from CssN was similar in all
groups of patients, demonstrating that the higher
variability of the apparent CL in the group of elderly
patients is mainly due to their lower serum albumin
concentrations (Table I).
A high prevalence of ultrasound-diagnosed non-
alcoholic fatty liver disease has been previously dem-
onstrated in adolescents (29) and adults (30,31)
chronically treated with VPA. Fatty liver disease
ranges from simple liver steatosis to steatohepatitis
with necroinﬂammation and liver ﬁbrosis, which can
progress to cryptogenic cirrhosis, and signiﬁcant
changes occur in hepatic drug-metabolizing cyto-
chrome P450 (CYP) enzyme families during these
progressive stages (32). Although the principal path-
ways of VPA metabolism are glucuronidation and
b-oxidation, and CYPs pathways account for less
than 10% of the dose (33), functional polymorphisms
of several cytochrome oxidase isoenzymes may
explain part of the inter-individual variability in
VPA pharmacokinetics (34). In accordance with pre-
viously published results (35), data indicated above
for APRI suggest a low likelihood of signiﬁcant liver
ﬁbrosis in epileptic patients treated with VPA in
monotherapy, even in elderly subjects (Table I); how-
ever, signiﬁcant negative correlations were obtained
between the apparent CLN of VPA and the APRI
score and AST/ALT ratio.
Induction of CYPs and GGT by enzyme-inducing
anticonvulsant drugs is widely documented and in
epileptic patients treated with VPA in monotherapy
and polytherapy with carbamazepine, phenytoin, or
phenobarbital; a signiﬁcant correlation has been pre-
viously reported between the apparent CL of VPA and
ALT and GGT serum activities (33). In our patients
that were treated with VPA in monotherapy, signiﬁ-
cant positive correlations were also found between the
apparent CLN of VPA and serum GGT and ALT.
VPA is not an enzyme-inducing agent, and in these
patients GGT and ALT activities may be associated
with over-weight and fat accumulation in the liver
(33,35). Although in simple steatosis the function of
several liver CYPs isoenzymes may be impaired, the
activity of phase II conjugation enzymes, such as
UDP-glucuronyltransferase, would be enhanced
(36), with the consequent increase of VPA biotrans-
formation and elimination.
The main limitation of our study is that the VPA
free fraction was not experimentally determined.
Endogenous substances such as free fatty acids,
uremic compounds, and bilirubin may displace
VPA from its albumin binding sites, increasing the
unbound fraction and leading to an underestimation
of the normalized CssN values. Free fatty acids
commonly increase after fasting states, and in our
study blood samples were taken before breakfast; in
none of our patients was a situation of renal failure or
jaundice observed. Although theoretical estimation
of normalized CssN concentrations offers approxi-
mate results (14), this pharmacokinetic approach
permits evaluation of the confounding effect of the
albumin concentration on the apparent CL of VPA
in old age.
In conclusion, total serum levels of VPA should be
considered with caution, principally in older patients,
in which determination of the drug unbound concen-
trations, or at least normalized total drug levels for
42 g/L albumin concentration, may be clinically use-
ful. Normalization of total VPA levels permits esti-
mation of a decrease around 40% for the apparent CL
in elderly patients.
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